Immunochemotherapy with CBDCA and anti-PD-1 antibodies before surgery present sustainable protection against secondary tumors by increasing CCL4 expression in the tumor and subsequently CD103+DC and CD8+ T cells infiltration in the tumor microenvironment in mouse TNBC models. This evidence concerns the gene PDCD1 and neoplasm.